Abstract
The effects of agmatine, an endogenous polyamine metabolite formed by decarboxylation of L-arginine, and its combination with morphine on conditioned place preference (CPP) has been investigated in male mice. Our data show that subcutaneous administration of morphine (1–7.5 mg/kg) significantly increases the time spent in the drug-paired compartment in a dose-dependent manner. Intraperitoneal administration of agmatine (1–40 mg/kg) alone does not induce either CPP or conditioned place aversion, while combination of agmatine and subeffective doses of morphine leads to potent rewarding effects. Lower doses of morphine (0.1, 0.05, and 0.01 mg/kg) are able to induce CPP in mice pretreated with agmatine 1, 5, and 10 mg/kg, respectively. Concomitant intraperitoneal administration of UK 14 304 (0.5 mg/kg), a highly selective α2-agonist, with per se noneffective dose of morphine (0.5 mg/kg) and also its combination with noneffective doses of agmatine (1 mg/kg) plus morphine (0.05 mg/kg) produces significant CPP. UK 14 304 (0.05, 0.5 mg/kg) alone, or in combination with agmatine (1, 5 mg/kg) have had no effect. We have further investigated the possible involvement of the α2-adrenoceptors in the potentiating effect of agmatine on morphine-induced place preference. Selective α2-antagonists, yohimbine (0.005 mg/kg) and RX821002 (0.1, 0.5 mg/kg), block the CPP induced by concomitant administration of agmatine (5 mg/kg) and morphine (0.05 mg/kg). Yohimbine (0.001–0.05 mg/kg) or RX821002 (0.05–0.5 mg/kg) alone or in combination with morphine (0.05 mg/kg) or agmatine (5 mg/kg) fail to show any significant place preference or aversion. Our results indicate that pretreatment of animals with agmatine enhances the rewarding properties of morphine via a mechanism which may involve α2-adrenergic receptors.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Anderson F, Paluzzi P, Lee J, Huggins G, Svikis D (1997). Illicit use of clonidine in opiate-abusing pregnant women. Obstet Gynecol 90: 790–794.
Aricioglu F, Ercil E, Dulger G (2003). Agmatine inhibits naloxone-induced contractions in morphine-dependent Guinea pig ileum. Ann NY Acad Sci 1009: 147–151.
Aricioglu F, Means A, Regunathan S (2004). Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. Eur J Pharmacol 504: 191–197.
Aricioglu-Kartal F, Regunathan S (2002). Effect of chronic morphine treatment on the biosynthesis of agmatine in rat brain and other tissues. Life Sci 71: 1695–1701.
Aricioglu-Kartal F, Uzbay IT (1997). Inhibitory effect of agmatine on naloxone precipitated abstinence syndrome in morphine dependent rats. Life Sci 61: 1775–1781.
Asin KE, Wirtshafter D (1985). Clonidine produces a conditioned place preference in rats. Psychopharmacology 85: 383–385.
Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31–43.
Bardo MT, Miller JS, Neisewander JL (1984). Conditioned place preference with morphine: the effect of extinction training on the reinforcing CR. Pharmacol Biochem Behav 21: 545–549.
Belzung C, Barreau S (2000). Differences in drug-induced place conditioning between BALB/c and C57B1/6 mice. Pharmacol Biochem Behav 65: 419–423.
Beuger M, Tommasello A, Schwartz R, Clinton M (1998). Clonidine use and abuse among methadone program applicants and patients. J Subst Abuse Treatment 15: 589–593.
Bricca G, Greney H, Zhang J, Dontenwill M, Stutzmann J, Belourt A et al (1993). Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br J Pharmacol 110: 1537–1543.
Cambridge D (1981). UK 14 304, a potent and selective α2-agonist for the characterization of α-adrenoceptor subtypes. Eur J Pharmacol 72: 413–415.
Cao BJ, Rodgers RJ (1997). Anxiolytic-like profile of p-MPPI, a novel 5HT1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology 129: 365–371.
Clarke RW, Harris J (2002). RX821002 as a tool for physiological investigation of alpha (2)-adrenoceptors. CNS Drug Rev 8: 177–192.
Demehri S, Homayoun H, Honar H, Riazi K, Vafaie K, Roushanzamir F et al (2003). Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 45: 534–542.
Dwoskin LP, Neal BS, Sparber SB (1983). Yohimbine exacerbates and clonidine attenuates acute morphine withdrawal in rats. Eur J Pharmacol 90: 269–273.
Ernsberger P, Meeley MP, Mann JJ, Reis DJ (1987). Clonidine binds to imidazole binding sites as well as α2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 131: 1–13.
Ernsberger P, Westbrooks KL, Christen MO, Schaffer SG (1992). A second generation of centrally acting antihypertensive agents act on putative I1–imidazoline receptors. J Cardiovasc Pharmacol 20 (Suppl 4): S1–S10.
Fairbanks CA, Schreiber KL, Brewer KL, Yu CG, Stone LS, Kitto KF et al (2000). Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 97: 10584–10589.
File SE (1986). Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res 21: 189–194.
Galitzky J, Senard JM, Lafontan M, Stillings M, Montastruc JL, Berlan M (1990). Identification of human platelet α2-adrenoceptors with a new antagonist [3H]-RX821002, a 2-methoxy derivative of idazoxan. Br J Pharmacol 100: 862–866.
Gold MS, Redmond DE, Kelger HD (1987). Clonidine blocks acute opiate withdrawal symptoms. Lancet 16: 599–602.
Goldberg MR, Robertsson D (1983). Yohimbine: a pharmacological probe for study of the alpha2-adrenoceptor. Pharmacol Rev 35: 143–180.
Gonzalez C, Regunathan S, Reis DJ, Estrada C (1996). Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharmacol 119: 677–684.
Hamilton CA, Reid JL, Yakubu MA (1988). [3H]Yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol 146: 345–348.
Iglesias V, Alguacil LF, Alamo C, Cuenca E (1992). Effects of yohimbine on morphine analgesia and physical dependence in the rat. Eur J Pharmacol 211: 35–38.
Jurkiewicz NH, Garcez do Carmo L, Hirata H, da Costa Santos W, Jurkiewicz A (1996). Functional properties of agmatine in rat. Eur J Pharmacol 307: 299–304.
Kekesi G, Dobos I, Benedek G, Horvath G (2004). The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: adenosine, agmatine, and endomorphin-1. Anesth Analg 98: 420–426.
Kolesnikov Y, Jain S, Pasternak GW (1996). Modulation of opioid analgesia by agmatine. Eur J Pharmacol 296: 17–22.
Kosten TA (1994). Clonidine attenuates conditioned aversion produced by naloxoneprecipitated opiate withdrawal. Eur J Pharmacol 254: 59–63.
Langroudi RM, Khoshnoodi MA, Abadi NYF, Fahadan PT, Ghahremani MH, Dehpour AR (2005). Effect of cyclosporin A on morphine-induced place conditioning in mice: involvement of nitric oxide. Eur J Pharmacol 507: 107–115.
Lavinsky D, Arteni NS, Netto CA (2003). Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 141: 19–24.
Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ (1994). Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263: 966–969.
Li J, Li X, Pei G, Qin BY (2002). Effects of agmatine on tolerance to and substance dependence on morphine in mice. Acta Pharmacol Sin 20: 232–238.
Liang M, Eason MG, Jewell-Motz EA, Williams MA, Theiss CT, Dorn II GW et al (1998). Phosphorylation and functional desensitization of the alpha2A-adrenergic receptor by protein kinase C. Mol Pharmacol 54: 44–49.
Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180–185.
Lu G, Su RB, Li J, Qin BY (2003). Modulation by alpha-difluoromethyl-ornithine and aminoguanidine of pain threshold, morphine analgesia and tolerance. Eur J Pharmacol 478: 139–144.
Maldoado R (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 21: 91–104.
Miralles A, Olmos G, Sastre M, Barturen F, Martin I, Garcia A-Sevilla JA (1993). Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]-RX821002 (2-methoxyidazoxan) in the human and rat brains. J Pharmacol ExpTher 264: 1187–1197.
Morales L, Perez-Garcia C, Alguacil LF (2001). Effects of yohimbine on the antinociceptive and place conditioning effects of opioid agonists in rodents. Br J Pharmacol 133: 172–178.
Morgan AD, Campbell UC, Fons RD, Carroll ME (2002). Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav 72: 873–880.
Nader K, van der Kooy D (1996). Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawn rats. Behav Neurosci 110: 389–400.
Onal A, Soykan N (2001). Agmatine produces antinociception in tonic pain in mice. Pharmacol Biochem Behav 69: 93–97.
Pellow S, File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24: 525–529.
Piletz JE, Chikkala DN, Ernsberger P (1995). Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther 272: 581–587.
Pineda J, Ruiz-Ortega JA, Martin-Ruiz R, Ugedo L (1996). Agmatine does not have activity at alpha 2-adrenoceptors which modulate the firing rate of locus coeruleus neurons: an electrophysiological study in rat. Neurosci Lett 219: 103–106.
Pinthong D, Wright IK, Hanmer C, Millns P, Mason R, Kendall DA et al (1995). Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 351: 10–16.
Raasch W, Schafer U, Chun J, Dominiak P (2001). Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 133: 755–780.
Reis DJ, Regunathan S (1998). Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 72: 80–85.
Reis DJ, Regunathan S (2000). Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21: 187–193.
Riazi K, Honar H, Homayoun H, Rashidi N, Kiani S, Ebrahimkhani MR et al (2005). The synergistic anticonvulsant effect of agmatine and morphine: Possible role of alpha-2 adrenoceptors. Epilepsy Res 65: 33–40.
Roerig SC (2003). Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann NY Acad Sci 1009: 116–126.
Ruiz-Durantez E, Llorente J, Ulibarri I, Pineda J, Ugedo L (2003). Agmatine-morphine interaction on nociception in mice. Ann NY Acad Sci 1009: 133–136.
Ruiz-Durantez E, Ruiz-Ortega JA, Pineda J, Ugedo L (2002). Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br J Pharmacol 135: 1152–1158.
Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J (2000). Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 130: 146–152.
Sanders MJ, Wiltgen BJ, Fanselow MS (2003). The place of the hippocampus in fear conditioning. Eur J Pharmacol 463: 217–223.
Saunders C, Limbird LE (1999). Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 84: 193–205.
Senard JM, Langin D, Estan L, Paris H (1990). Identification of a2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells. Eur J Pharmacol 191: 59–68.
Schulteis G, Stinus L, Risbrough VB, Koob GF (1998). Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. Neuropsychopharmacology 19: 406–416.
Suzuki T, Tsuda M, Funada M, Misawa M (1995). Blockade of morphine-induced place preference by diazepam in mice. Eur J Pharmacol 280: 327–330.
Tabor CW, Tabor H (1984). Polyamines. Annu Rev Biochem 53: 749–790.
Tierney C, Nadaud D, Koenig-Berard E, Stinus L (1988). Effects of two alpha 2 agonists, rilmenidine and clonidine, on the morphine withdrawal syndrome and their potential addictive properties in rats. Am J Cardiol 61: 35–38.
Tzschentke TM (1998). Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56: 613–672.
Tzschentke TM, Schmidt WJ (1997). Interaction of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and conditioning behavioral sensitization. Behav Brain Res 84: 99–107.
Utkan T, Ulak G, Yildiran HG, Yardimoglu M, Gacar MN (2000). Investigation on the mechanism involved in the effects of agmatine on ethanol-induced gastric mucosal injury in rats. Life Sci 66: 1705–1711.
Uzbay IT, Yesilyurt O, Celik T, Ergun H, Isimer A (2000). Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 107: 153–159.
Yesilyurt O, Uzbay IT (2001). Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 25: 98–103.
Zarrindast MR, Faraji N, Rostami P, Sahraei H, Ghoshouni H (2003). Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav 74: 363–369.
Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL (2002). Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13: 387–391.
Acknowledgements
We thank Drs S Ejtemaei-Mehr and K Riazi for their helpful criticisms on this manuscript. This study was supported by Grant 132-10555 from the Vice-Chancellor for Research of Tehran University of Medical Sciences to MHG.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tahsili-Fahadan, P., Yahyavi-Firouz-Abadi, N., Khoshnoodi, M. et al. Agmatine Potentiates Morphine-Induced Conditioned Place Preference in Mice: Modulation by Alpha(2)-Adrenoceptors. Neuropsychopharmacol 31, 1722–1732 (2006). https://doi.org/10.1038/sj.npp.1300929
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300929
Keywords
This article is cited by
-
Effects of imidazoline agents in a rat conditioned place preference model of addiction
Naunyn-Schmiedeberg's Archives of Pharmacology (2022)
-
Inhibition of NMDA receptors by agmatine is followed by GABA/glutamate balance in benzodiazepine withdrawal syndrome
Beni-Suef University Journal of Basic and Applied Sciences (2021)
-
A Nonrewarding NMDA Receptor Antagonist Impairs the Acquisition, Consolidation, and Expression of Morphine Conditioned Place Preference in Mice
Molecular Neurobiology (2017)
-
Cloning of two LIMCH1 isoforms: characterization of their distribution in rat brain and their agmatinase activity
Histochemistry and Cell Biology (2016)
